United Therapeutics to Present Phase 3 TETON-2 Data for Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis at ERS Congress
Key Insights
United Therapeutics will present results from the successful phase 3 TETON-2 study of inhaled treprostinil for idiopathic pulmonary fibrosis (search) at the European Respiratory Society Congress.
The company will also share interim data from the ADVANCE EXTENSION study evaluating ralinepag for pulmonary arterial hypertension (search) and findings from the PHINDER study.
Multiple presentations are scheduled for September 27-October 1, 2025, including oral presentations and poster sessions covering various respiratory conditions.
United Therapeutics Corporation announced it will present clinical data across its commercial and development portfolio at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands, from September 27 to October 1, 2025. The presentations will feature results from the successful phase 3 TETON-2 study of inhaled treprostinil in idiopathic pulmonary fibrosis (search), marking a significant milestone for the company's respiratory disease pipeline.
Key Clinical Data Presentations
The company will deliver multiple presentations highlighting advances in treating various respiratory conditions. "On the heels of the remarkable topline results announced earlier this month, we are excited to present additional analyses from the TETON-2 study at ERS this year," said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics.
TETON Studies in Pulmonary Fibrosis
Two oral presentations will focus on inhaled treprostinil for pulmonary fibrosis treatment. Steven D. Nathan, M.D., FCCP, from Inova Fairfax Hospital will present both the TETON Phase 3 Clinical Trials results for idiopathic pulmonary fibrosis (search) and the TETON-PPF Clinical Trial data for progressive pulmonary fibrosis (search). These presentations are scheduled for Sunday, September 28, from 11:00 a.m. to 12:15 p.m. CET.
PHINDER Study for Enhanced Detection
The PHINDER study represents an innovative approach to improving pulmonary hypertension (search) detection in patients with interstitial lung disease (search). Sandeep Sahay, M.D., FCCP, from Houston Methodist Hospital will present interim results focusing on pulmonary hypertension screening for earlier detection. Additionally, David Kiely, M.D., B.Sc. (Hons), FRCP, from the University of Sheffield will share high-resolution computed tomography findings from patients with pulmonary hypertension associated with interstitial lung disease.
Nelsen emphasized the potential clinical impact: "We believe [the PHINDER study] will improve detection of pulmonary hypertension (search) in patients with interstitial lung disease (search)."
Ralinepag Extension Study
Colin Church, M.D., B.Sc. (Hons), Ph.D., FRCP from the University of Glasgow will present risk improvements data from the ralinepag open-label extension study. This presentation, scheduled for Tuesday, September 30, will provide additional interim data from the ADVANCE EXTENSION study evaluating ralinepag for pulmonary arterial hypertension (search).
Conference Schedule
The presentations span multiple days and formats:
- Sunday, September 28: Two oral presentations on TETON studies (11:00 a.m. to 12:15 p.m. CET) and two poster sessions on PHINDER study findings (12:30 p.m. to 2:00 p.m. CET)
- Tuesday, September 30: Poster session on ralinepag extension data (8:00 a.m. to 9:30 a.m. CET)
The comprehensive presentation schedule demonstrates United Therapeutics' commitment to advancing treatment options across multiple respiratory conditions, from rare pulmonary diseases to more common complications affecting patients with interstitial lung disease (search).